The research program “Pharmaceutical Biotechnology: Science for Health” (P4-0127) focuses on investigating the fundamental molecular mechanisms of cellular function and the disruptions that arise, contributing to the development and progression of various diseases, including cancer, neurodegenerative, and immune diseases.
In cancer research, we study the activity of proteolytic enzymes and develop specific inhibitors that can prevent tumor invasion and metastasis. By regulating proteolytic enzymes involved in immune responses, we aim to enhance the antitumor immune response and develop new forms of immuno- and cell-based cancer therapies. We are investigating novel ways of modulating the immune response to develop targeted therapies that are more effective and cause fewer undesirable side effects. Additionally, we examine the interactions between the tumor microenvironment and the immune system and strive to identify key signaling pathways that allow tumors to evade immune surveillance. We use advanced technologies to better understand how tumor tissue adapts its biological activity and responds to therapy. By developing new immunotherapeutic strategies, we aim to achieve more selective and sustainable destruction of cancer cells. We also explore combination therapies that integrate immunotherapy with existing treatment methods to improve therapeutic response and reduce the likelihood of disease recurrence.
Cancer represents one of the greatest healthcare burdens in modern societies, as its incidence is rising. The increased incidence of cancer places a greater burden on the healthcare system and society as a whole, as treatment costs are high, and patients often require long-term care. Therefore, it is crucial to invest in improved prevention, earlier diagnosis, and more effective therapies that could help reduce mortality and improve patients’ quality of life. Our work employs modern methods of molecular biology, biochemistry, cell biology, and bioinformatics. Our research is interdisciplinary and involves collaboration with numerous national and international research institutions and the pharmaceutical industry. Through our efforts, we aim to contribute to reducing the disease burden in society, improving healthcare services, and fostering the development of pharmaceutical biotechnology as a key field for the future of medicine. Understanding the molecular mechanisms of diseases allows us to develop targeted treatment approaches that are more effective and tailored to the individual.
Link to the research program presentation: https://cris.cobiss.net/ecris/si/en/project/17661